Article
Resistance-associated substitutions in patients with chronic hepatitis C virus genotype 4 infection.
Journal of viral hepatitis - 1 Oct 2020
Dietz Julia, Kalinina Olga V, Vermehren Johannes, Peiffer Kai-Henrik, Matschenz Katrin, Buggisch Peter, Niederau Claus, Schattenberg Jörn M, Müllhaupt Beat, Yerly Sabine, Ringelhan Marc, Schmid Roland M, Antoni Christoph, Müller Tobias, Schulze Zur Wiesch Julian, Piecha Felix, Moradpour Darius, Deterding Katja, Wedemeyer Heiner, Moreno Christophe, Berg Thomas, Berg Christoph P, Zeuzem Stefan, Welsch Christoph, Sarrazin Christoph
Abstract excerpt
Data on the prevalence of resistance-associated substitutions (RASs) and their implications for treatment with direct-acting antivirals (DAAs) are sparse in European patients with HCV genotype 4. This study investigated RASs before and after DAA failure in different genotype 4 subtypes and evaluated retreatment efficacies. Samples of 195 genotype 4-infected patients were collected in the European Resistance...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
